Launch of the 'AI New Drug Development Expert Committee'... Building a Collaborative Ecosystem in Pharma Bio

On the 28th of last month, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association's 'AI New Drug Development Expert Committee' was held at the Grand InterContinental Seoul Parnas in Gangnam-gu, Seoul. [Photo by Korea Pharmaceutical and Bio-Pharma Manufacturers Association]

Industry experts gathered to promote digital transformation through artificial intelligence (AI) in the research and development (R&D) sector of the pharmaceutical and bio industry and to activate the data utilization ecosystem.

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association's AI New Drug Development Support Center announced on the 2nd that it has launched the 'AI New Drug Development Expert Committee,' composed of experts from 19 pharmaceutical and bio companies, and held its first meeting.

The committee plans to conduct quarterly regular meetings to discuss R&D issues, share issues and trends in AI new drug development, foster field-oriented professionals, and discover government policy tasks utilizing big data.

At the first meeting, the committee discussed implementation plans for this year's AI New Drug Development Support Center projects, including the AI New Drug Development Competition and the AI New Drug Development Ecosystem Activation Workshop. In particular, they agreed on the necessity of the 'Korean-style AI New Drug Development Research Cooperation Model Project,' which enables effective utilization of data held by other institutions without concerns about leakage of sensitive healthcare data, and decided to actively participate. Additionally, Han Tae-dong, Executive Director of Dong-A ST, was appointed as the inaugural chairman.

Chairman Han said, "Industry-academia-research cooperation, essential for enhancing AI new drug development competitiveness, can be realized through the establishment of a close cooperative research system among industry, universities, and public institutions based on strong government leadership." He added, "Once a data linkage collaboration system between companies, between companies and universities, and between companies and public institutions is established, low-cost and high-efficiency new drug development R&D investment is expected to be possible."

This content was produced with the assistance of AI translation services.